CRISPR Therapeutics AGCRSPNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
-9.36%
↑ 86% vs avg
Percentile
P49
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-64.87%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -9.36% |
| Q3 2025 | 25.68% |
| Q2 2025 | -111.10% |
| Q1 2025 | -7.83% |
| Q4 2024 | 53.20% |
| Q3 2024 | -11.85% |
| Q2 2024 | -187.09% |
| Q1 2024 | 214.24% |
| Q4 2023 | -141.05% |
| Q3 2023 | 70.09% |
| Q2 2023 | -1614.32% |
| Q1 2023 | 107.76% |
| Q4 2022 | -7.71% |
| Q3 2022 | 25.88% |
| Q2 2022 | -4.97% |
| Q1 2022 | -57.19% |
| Q4 2021 | -5.79% |
| Q3 2021 | -110.08% |
| Q2 2021 | 901.69% |
| Q1 2021 | -23.95% |
| Q4 2020 | -7.28% |
| Q3 2020 | -158.55% |
| Q2 2020 | 43.88% |
| Q1 2020 | -1645.47% |
| Q4 2019 | -97.47% |
| Q3 2019 | 466.72% |
| Q2 2019 | 16.82% |
| Q1 2019 | -54.16% |
| Q4 2018 | -42.12% |
| Q3 2018 | 20.82% |
| Q2 2018 | -11.14% |
| Q1 2018 | -52.86% |
| Q4 2017 | 6.47% |
| Q3 2017 | 0.67% |
| Q2 2017 | 31.77% |
| Q1 2017 | -20.58% |
| Q4 2016 | -58.16% |
| Q3 2016 | 9.76% |
| Q2 2016 | -35.85% |
| Q1 2016 | -114.51% |